Skip to content

Advertisement

  • Letter
  • Open Access

Back-to-back comparison of penKID with NephroCheck® to predict acute kidney injury at admission in intensive care unit: a brief report

Critical Care201822:24

https://doi.org/10.1186/s13054-018-1945-9

  • Received: 20 November 2017
  • Accepted: 9 January 2018
  • Published:

Acute kidney injury (AKI) is a frequent condition in critically ill patients that affects both short- and long-term outcome [1]. Its early detection remains a challenge, and diagnosis frequently occurs too late with cell damage already present. Implementation of novel biomarkers that reliably identify patients at risk or at an early stage of AKI could offer more efficient management strategies leading to better outcomes.

In our investigation, we compared two promising AKI biomarkers: a marker of tubular injury commercialized as a lateral-flow test (NephroCheck®) [2], the product of urinary TIMP-2 (Tissue inhibitor of metalloprotease), and IGFBP 7 (Insulin-like growth factor binding protein; overall TIMP2xIGFBP7), and the filtration marker proenkephalin A 119-159 (penKid). penKid has been recently described as a valuable plasma biomarker of AKI in the acutely ill, including septic patients [3] and patients suffering from acute heart failure [4]. Proenkephalin represents a stable surrogate analyte of labile enkephalins, which are known as endogenous opioids, but also affects kidney function [5]. The aim of our study was to conduct a parallel assessment of the two biomarkers in an intensive care unit (ICU) population from the data of the FROG-ICU study.

FROG-ICU has been designed to better understand long-term outcome after ICU discharge as well as risk factors for all-cause and cardiovascular morbidity and associated mortality (FROG-ICU study, ClinicalTrials.gov identifier NCT01367093). It was a large prospective multicenter cohort study with biological (plasma and urine) collection and one-year follow-up of ICU patients. FROG-ICU aims to allow risk stratification of ICU survivors in order to recognize the subset of patients who may benefit from early intervention to allow decreased cardiovascular morbidity and related mortality. The methodology of the FROG-ICU study was published in 2015. From the FROG study including 2087 critically ill patients we randomly selected 200 requiring mechanical ventilation or vasopressor support for more than 24 h with respect to the four categories of the renal Sequential Organ Failure Assessment (SOFA) score (i.e., creatinine level on admission of < 1.2 mg/dL (n = 80), 1.2 to 1.9 mg/dL (n = 40), 2 to 3.4 mg/dL (n = 40), and ≥ 3.5 mg/dL (n = 40)); 78% were male, with a median age of 65 years (interquartile range (IQR) 54–75). In the investigated cohort of a standard population of critically ill, the main cause of ICU admission was septic shock (26%), the median age was 65 years (IQR 54–75), the median SAPS II score was 51 (IQR 41–68), and the ICU mortality was 26%. Other causes of admission include out-of-hospital cardiac arrest (10%), acute respiratory failure (16%), acute neurological disorder (11%), and cardiogenic shock (8%). On ICU admission, the median (and IQR) value of estimated glomerular filtration rate for penKid and TIMP2xIGFBP7 was 47 mL/min (22–88), 85 pmol/L (48–40), and 0.6 UNIT (0.3–2), respectively.

AKI was defined using the Kidney Disease Improvement Global Outcome (KDIGO) definition. Accordingly, we used both the variation in serum creatinine during the first 48 h after ICU admission and the maximal value during the 7 days following ICU admission. Admission serum creatinine was used as baseline serum creatinine when the estimated glomerular filtration rate (eGFR) was above 60 ml/min/1.73 m2 at admission. Otherwise (n = 117, 59% of the study population), baseline serum creatinine was extrapolated considering a baseline eGFR of 75 ml/min/1.73 m2 (based on the MDRD (Modification of Diet in Renal Disease) equation). Both penKid and TIMP2xIGFBP7 were measured on ICU admission in plasma and urine. We assessed the conformity of penKid and TIMP2xIGFBP7 for prediction or detection of AKI as defined by the KDIGO classification, with the renal SOFA score, by the area under the ROC curve. On ICU admission, the median (and IQR) value of eGFR for penKid and NephroCheck® was 47 mL/min/1.73 m2 (22–88), 85 pmol/L (48–40), and 0.6 UNIT (0.3–2), respectively. Figure 1 shows correlation of penKid and TIMP2xIGFBP7 levels on ICU admission with the severity of AKI, and confirms that penKid as a filtration marker shows a significantly higher association with AKI (ROC curve 0.668 (95% CI 0.589–0.743) vs 0.908 (95% CI 0.868–0.944), p < 0.0001). When investigating renal replacement therapy (RRT) as an outcome parameter, elevated penKid levels were able to more accurately predict need of RRT in our standard ICU population (n = 60) when compared to elevated TIMP2xIGFBP7 levels (AUC [95% CI] 0.778 [0.713–0838] and 0.678 [0.597–0.761]). Limitations of our investigation include a possible sampling bias within the investigated population as we didn’t measure the two biomarkers in the whole cohort of 2087 patients.
Fig. 1
Fig. 1

Boxplot of penKid (grey) and NephroCheck (white) levels according to severity of AKI as defined by KDIGO (left panel) and respective ROC curves predicting AKI (right panel)

Declarations

Acknowledgements

The authors are particularly grateful to Marie-Céline Fournier, who coordinated organizational aspects of the study. We also thank the Centre de Recherche Clinique (CRC) of Lariboisière University Hospital for his support.

Investigators for the FROG-ICU study are:

Hôpital Lariboisière (Paris): N. Deye, C. Fauvaux, A. Mebazaa, C. Damoisel, D. Payen, E. Gayat, M. Legrand.

Hôpital Saint Louis (Paris): E. Azoulay, A.-S. Moreau, L. Jacob, O. Marie.

Hôpital Bichat (Paris): M. Wolf, R. Sonneville, R. Bronchard.

Hôpital Beaujon (Clichy): I. Rennuit, C. Paugam.

Hôpital Cochin (Paris): J.-P. Mira, A. Cariou, A. Tesnieres.

Hôpital Bicêtre (Le Kremlin-Bicêtre): N. Dufour, N. Anguel, L. Guerin, J. Duranteau, C. Ract.

CHU de Marseille (Marseille): M. Leone, B. Pastene.

Hôpital Raymond Poincaré (Garches): T. Sharshar, A. Fayssoyl.

Hôpital Saint-Antoine: J.-L. Baudel, B. Guidet.

Hôpital de la Pitié—Salpêtrière (Paris): Q. Lu, W.-J. Gu, N. Brechot, A. Combes.

CHU St Eloi (Montpellier): S. Jaber, A. Pradel, Y. Coisel, M. Conseil.

Hôpital Ambroise Paré (Boulogne): A. Veillard-Baron, L. Bodson.

CHU Caremeau (Nîmes): J.Y. Lefrant, L. Elotmani, A. Ayral, S. Lloret.

Hôpital Jean Minjoz (Besançon): S. Pily-Flouri, J.-B. Pretalli.

Clinique Saint-Luc (Belgium): P.-F. Laterre, V. Montiel, M.-F. Dujardin, C. Berghe.

Funding

FROG-ICU (ClinicalTrials.gov identifier NCT01367093) was funded by the Programme Hospitalier de la Recherche Clinique (AON 10-216) and by a research grant from the Société Française d’Anesthésie—Réanimation.

Abbot, sphingotec, Roche Diagnostics and Critical Diagnostics provided unrestricted free kits to Assistance Publique—Hôpitaux de Paris to conduct biomarker analyses.

Availability of data and materials

Prof. Mebazaa had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Additional information

Figure 1 is an original provided by the first author (Etienne Gayat).

Authors’ contributions

Study concept and design: EG, AM. Acquisition of data: EG, AM, CT, AV-B. Analysis and interpretation of data: EG, AM. Drafting of the manuscript: EG, AH, AM. Critical revision of the manuscript for important intellectual content: all declared authors. Statistical analysis: EG. Obtained funding: EG, AM. Administrative, technical, or material support: EG, AM. Study supervision: EG, AM. All authors have read and approved the final manuscript.

Authors’ information

Cyril Touchard works as a resident in the Saint Louis Lariboisière University Hospitals. Alexa Hollinger works as a postdoctoral research fellow at the Saint Louis Lariboisière University Hospitals. The other authors are members of the steering committee and/or investigators in the FROG-ICU study.

Ethics approval and consent to participate

The study was conducted in France and Belgium in accordance with Good Clinical Practice (Declaration of Helsinki 2002) and Ethical Committee approvals (Comité de Protection des Personnes—Ile de France IV, IRB number 00003835 and Commission d’éthique biomédicale hospitalo-facultaire de l’hôpital de Louvain, IRB number B403201213352). It is registered on ClinicalTrials.gov (NCT01367093). Patients were included from August 2011 to June 2013.

Consent for publication

Not applicable.

Competing interests

Etienne Gayat received a research grant from sphingotec, consultancy fees from Magnisense, Roche Diagnostics. Alexandre Mebazaa received speaker’s honoraria from Abbott, Novartis, Orion, Roche et Servier and a fee as a member of the advisory board and/or Steering Committee from Cardiorentis, Adrenomed, MyCartis, Neurotronik, and sphingotec. All other co-authors have no conflicts of interest related to the present manuscript.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Anesthesiology, Critical Care and Burn Unit, Hôpitaux Universitaires Saint Louis—Lariboisière, Assistance Publique—Hôpitaux de Paris, Paris, France
(2)
Université Paris Diderot—Paris 7, Sorbonne Paris Cité, Paris, France
(3)
UMR-S 942, INSERM, Paris, France
(4)
University Hospital Ambroise Paré, Intensive Care Unit, Assistance Publique—Hopitaux de Paris, 26930 Boulogne-Billancourt, France
(5)
Department of Anesthesiology and Intensive Care, INSERM UMR-S 942, Saint Louis—Lariboisière University Hospitals, 2 rue Ambroise Paré, Paris, 75010, France

References

  1. Darmon M, Ostermann M, Cerda J3, Dimopoulos MA, Forni L, Hoste E, Legrand M, Lerolle N, Rondeau E, Schneider A, Souweine B, Schetz M. Diagnostic work-up and specific causes of acute kidney injury. Intensive Care Med. 2017;43(6):829–40. https://doi.org/10.1007/s00134-017-4799-8. Epub 2017 Apr 25.
  2. Bihorac A, Chawla LS, Shaw AD, Al-Khafaji A, Davison DL, Demuth GE, Fitzgerald R, Gong MN, Graham DD, Gunnerson K, Heung M, Jortani S, Kleerup E, Koyner JL, Krell K, Letourneau J, Lissauer M, Miner J, Nguyen HB, Ortega LM, Self WH, Sellman R, Shi J, Straseski J, Szalados JE, Wilber ST, Walker MG, Wilson J, Wunderink R, Zimmerman J, Kellum JA. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med. 2014;189:932–9.View ArticlePubMedGoogle Scholar
  3. Marino R, Struck J, Hartmann O, Maisel AS, Rehfeldt M, Magrini L, Melander O, Bergmann A, Di Somma S. Diagnostic and short-term prognostic utility of plasma pro-enkephalin (pro-ENK) for acute kidney injury in patients admitted with sepsis in the emergency department. J Nephrol. 2015;28:717–24.View ArticlePubMedGoogle Scholar
  4. Ng LL, Squire IB, Jones DJ, Cao TH, Chan DC, Sandhu JK, Quinn PA, Davies JE, Struck J, Hartmann O, Bergmann A, Mebazaa A, Gayat E, Arrigo M, Akiyama E, Sabti Z, Lohrmann J, Twerenbold R, Herrmann T, Schumacher C, Kozhuharov N, Mueller C, Network G. Proenkephalin, renal dysfunction, and prognosis in patients with acute heart failure: a GREAT Network study. J Am Coll Cardiol. 2017;69:56–69.View ArticlePubMedGoogle Scholar
  5. Sezen SF, Kenigs VA, Kapusta DR. Renal excretory responses produced by the delta opioid agonist, BW373U86, in conscious rats. J Pharmacol Exp Ther. 1998;287:238–45.PubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement